167 related articles for article (PubMed ID: 33749717)
1. A Budget Impact Analysis of Gene Therapy for Sickle Cell Disease: The Medicaid Perspective.
DeMartino P; Haag MB; Hersh AR; Caughey AB; Roth JA
JAMA Pediatr; 2021 Jun; 175(6):617-623. PubMed ID: 33749717
[TBL] [Abstract][Full Text] [Related]
2. Financial Implications of Avapritinib for Treatment of Unresectable Gastrointestinal Stromal Tumors in Patients With a PDGFRA Exon 18 Variant or After 3 Previous Therapies in a Hypothetical US Health Plan.
Proudman D; Miller A; Nellesen D; Gomes A; Mankoski R; Norregaard C; Sullivan E
JAMA Netw Open; 2020 Nov; 3(11):e2025866. PubMed ID: 33201235
[TBL] [Abstract][Full Text] [Related]
3. Gene Therapy Versus Common Care for Eligible Individuals With Sickle Cell Disease in the United States : A Cost-Effectiveness Analysis.
Basu A; Winn AN; Johnson KM; Jiao B; Devine B; Hankins JS; Arnold SD; Bender MA; Ramsey SD
Ann Intern Med; 2024 Feb; 177(2):155-164. PubMed ID: 38252942
[TBL] [Abstract][Full Text] [Related]
4. Targeted erlotinib for first-line treatment of advanced non-small cell lung cancer: a budget impact analysis.
Bajaj PS; Veenstra DL; Goertz HP; Carlson JJ
J Med Econ; 2014 Aug; 17(8):538-46. PubMed ID: 24716717
[TBL] [Abstract][Full Text] [Related]
5. Profile of Medicaid enrollees with sickle cell disease: A high need, high cost population.
Grady A; Fiori A; Patel D; Nysenbaum J
PLoS One; 2021; 16(10):e0257796. PubMed ID: 34705847
[TBL] [Abstract][Full Text] [Related]
6. Short-term budget affordability of hepatitis C treatments for state Medicaid programs.
Chou JW; Silverstein AR; Goldman DP
BMC Health Serv Res; 2019 Feb; 19(1):140. PubMed ID: 30819153
[TBL] [Abstract][Full Text] [Related]
7. Estimated Budget Impact of Adopting the Affordable Care Act's Required Smoking Cessation Coverage on United States Healthcare Payers.
Baker CL; Ferrufino CP; Bruno M; Kowal S
Adv Ther; 2017 Jan; 34(1):156-170. PubMed ID: 27888437
[TBL] [Abstract][Full Text] [Related]
8. Budget Impact Analysis of Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US.
Ghanem B; Shi L
Clin Drug Investig; 2022 Dec; 42(12):1085-1092. PubMed ID: 36316586
[TBL] [Abstract][Full Text] [Related]
9. A Qualitative Analysis of State Medicaid Coverage Benefits for Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Patients with Sickle Cell Disease (SCD).
Mupfudze TG; Preussler JM; Sees JA; SanCartier M; Arnold SD; Devine S
Transplant Cell Ther; 2021 Apr; 27(4):345-351. PubMed ID: 33836889
[TBL] [Abstract][Full Text] [Related]
10. Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid.
Zemplenyi A; Leonard J; DiStefano MJ; Anderson KE; Wright GC; Mendola ND; Nair K; McQueen RB
Pharmacoeconomics; 2024 Mar; 42(3):319-328. PubMed ID: 37989969
[TBL] [Abstract][Full Text] [Related]
11. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
[No Abstract] [Full Text] [Related]
12. Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans.
Li Y; Heer AK; Sloane HS; Edelstein DL; Tie J; Gibbs P; Barzi A
JAMA Health Forum; 2024 May; 5(5):e241270. PubMed ID: 38819797
[TBL] [Abstract][Full Text] [Related]
13. Budget Impact of Next-Generation Sequencing for Molecular Assessment of Advanced Non-Small Cell Lung Cancer.
Yu TM; Morrison C; Gold EJ; Tradonsky A; Arnold RJG
Value Health; 2018 Nov; 21(11):1278-1285. PubMed ID: 30442274
[TBL] [Abstract][Full Text] [Related]
14. Does capitated managed care affect budget predictability? Evidence from Medicaid programs.
Perez V
Int J Health Econ Manag; 2018 Jun; 18(2):123-152. PubMed ID: 29032436
[TBL] [Abstract][Full Text] [Related]
15. Early Performance in Medicaid Accountable Care Organizations: A Comparison of Oregon and Colorado.
McConnell KJ; Renfro S; Chan BK; Meath TH; Mendelson A; Cohen D; Waxmonsky J; McCarty D; Wallace N; Lindrooth RC
JAMA Intern Med; 2017 Apr; 177(4):538-545. PubMed ID: 28192568
[TBL] [Abstract][Full Text] [Related]
16. Budget impact of Medicaid Section 1115 demonstrations for early HIV treatment.
Schackman BR; Freedberg KA; Goldie SJ; Weinstein MC; Swartz K
Health Care Financ Rev; 2005; 26(4):67-80. PubMed ID: 17288069
[TBL] [Abstract][Full Text] [Related]
17. Implementing Lifestyle Change Interventions to Prevent Type 2 Diabetes in US Medicaid Programs: Cost Effectiveness, and Cost, Health, and Health Equity Impact.
Laxy M; Zhang P; Ng BP; Shao H; Ali MK; Albright A; Gregg EW
Appl Health Econ Health Policy; 2020 Oct; 18(5):713-726. PubMed ID: 32607728
[TBL] [Abstract][Full Text] [Related]
18. Comparison of risk-adjustment systems for the medicaid-eligible disabled population.
Payne SM; Cebul RD; Singer ME; Krishnaswamy J; Gharrity K
Med Care; 2000 Apr; 38(4):422-32. PubMed ID: 10752974
[TBL] [Abstract][Full Text] [Related]
19. Budgetary Impact of Telotristat Ethyl, a Novel Treatment for Patients with Carcinoid Syndrome Diarrhea: A US Health Plan Perspective.
Joish VN; Frech F; Lapuerta P
Clin Ther; 2017 Dec; 39(12):2338-2344. PubMed ID: 29175096
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
